Apart from these therapies mentioned above, newer approaches to treating MCL have demonstrated encouraging outcomes: cellular therapies like chimeric antigen receptor (CAR) T cells and bispecific T-cell splicer (BiTe) antibodies; targeted medicines like BTK and BCL2 inhibitors [4]. This evidence concerns the gene BCL2 and mantle cell lymphoma.